First or Second Biologic in Inflammatory Bowel Disease: Combination Therapy or Monotherapy?

Simple item page
dc.contributor.authorAoun, Roni
dc.contributor.authorJabak, Suha J.
dc.contributor.authorMourad, Fadi H.
dc.contributor.authorFrancis, Fadi F.
dc.contributor.authorRegueiro, Miguel D.
dc.contributor.authorHashash, Jana G.
dc.contributor.departmentInternal Medicine
dc.contributor.departmentDivision of Gastroenterology and Hepatology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:01:19Z
dc.date.available2025-01-24T12:01:19Z
dc.date.issued2021
dc.description.abstractThe therapeutic armamentarium for patients with inflammatory bowel disease has been expanding. Current guidelines make recommendations about whether patients who are biologic naive should be receiving biologic monotherapy or combination therapy, depending on the class of biologics. However, due to the limited available data, guidance to inform clinical practice for patients receiving their second or more biologic are lacking. We hereby review the available data about the use of biologic monotherapy or combination therapy with concomitant immunomodulator therapies in patients receiving their first as well as those receiving their second biologic. © 2021 Lippincott Williams and Wilkins. All rights reserved.
dc.identifier.doihttps://doi.org/10.1097/MCG.0000000000001591
dc.identifier.eid2-s2.0-85115354161
dc.identifier.pmid34294654
dc.identifier.urihttp://hdl.handle.net/10938/31447
dc.language.isoen
dc.publisherLippincott Williams and Wilkins
dc.relation.ispartofJournal of Clinical Gastroenterology
dc.sourceScopus
dc.subjectBiologic
dc.subjectCombination therapy
dc.subjectIbd
dc.subjectImmunogenicity
dc.subjectMonotherapy
dc.subjectBiological products
dc.subjectColitis
dc.subjectCombined modality therapy
dc.subjectDrug therapy, combination
dc.subjectHumans
dc.subjectImmunologic factors
dc.subjectInflammatory bowel diseases
dc.subjectBiological product
dc.subjectImmunomodulating agent
dc.subjectTumor necrosis factor inhibitor
dc.subjectUstekinumab
dc.subjectVedolizumab
dc.subjectImmunologic factor
dc.subjectBiological therapy
dc.subjectClinical outcome
dc.subjectComparative effectiveness
dc.subjectHuman
dc.subjectImmunotherapy
dc.subjectInflammatory bowel disease
dc.subjectPractice guideline
dc.subjectReview
dc.subjectCombination drug therapy
dc.subjectMultimodality cancer therapy
dc.titleFirst or Second Biologic in Inflammatory Bowel Disease: Combination Therapy or Monotherapy?
dc.typeReview

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
2021-2341.pdf
Size:
195.14 KB
Format:
Adobe Portable Document Format
Download

Collections

Internal Medicine